Atazanavir pharmacokinetics with and without tenofovir during pregnancy - Wikidata - wikimedia - TriplyDB

Atazanavir pharmacokinetics with and without tenofovir during pregnancy

Atazanavir pharmacokinetics with and without tenofovir during pregnancy

http://www.wikidata.org/entity/Q35074548

about

Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.Antenatal atazanavir: a retrospective analysis of pregnancies exposed to atazanavir.Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics.Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.Effect of pregnancy on emtricitabine pharmacokinetics.Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy.Meconium Atazanavir Concentrations and Early Language Outcomes in HIV-Exposed Uninfected Infants With Prenatal Atazanavir Exposure.Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.Reduced indinavir exposure during pregnancy.Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy.Obstetric Pharmacokinetic Dosing Studies are Urgently Needed.Antiretroviral use during pregnancy for treatment or prophylaxis.Pharmacokinetic optimization of antiretroviral therapy in pregnancy.Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.HIV protease inhibitors in pregnancy : pharmacology and clinical use.British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review).Antiretroviral Pharmacokinetics in Pregnant Women.Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.Quantitative determination of free/bound atazanavir via high-throughput equilibrium dialysis and LC-MS/MS, and the application in ex vivo samples.Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients.Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.British HIV Association guidelines for the management of HIV infection in pregnant women 2012 PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics

P2860

Q28109657-50917C77-33B7-48FF-A204-DB34B451F606 Q33365566-B29A86F3-2D50-4B07-98BF-D39F8B68829E Q33760652-0D6358A6-5B92-449B-B251-251DDE850D81 Q34310482-A01B930D-AAEF-4B49-BCB3-F4F543138CD7 Q34429204-A936E597-3F62-41D8-8045-E1710456496A Q34511184-4060C717-1D69-4F8C-9F76-3CC8F5276347 Q35060812-E7920188-A0D8-467C-9B71-8D87577D33FC Q35659264-F0EC0176-9C94-436F-BAFB-71DE3DA4C16B Q35784583-DBC6F037-444B-4243-9207-EFBCFF9F26EB Q35930696-79D5DA32-562D-4553-8243-957E9D73E907 Q36084313-4D8C2E44-53F8-415A-AA71-850A4009AA10 Q36599597-02264AC0-B642-4B2A-8B0C-12CDAB47B4F6 Q36763067-B74840C7-8B18-4EF3-A303-3D5A611DA923 Q36930395-438EDEF2-AF34-4995-8499-673E00EE182A Q36951911-5201F34C-6DF5-48D1-A5B5-C263F14F27AC Q37013956-7E9182B1-82C2-418D-A133-12FBDD98DE56 Q37161917-E8A50141-6043-45E1-BB2F-0E956F0BA99F Q37204113-6B52D9D2-463F-452B-AF23-102BF4260B60 Q37575742-7926E6E4-E88E-48DE-ACED-6FD38F423F02 Q37870932-F1C16040-CCB9-49F0-A88A-E22C81CF19DD Q38047214-075DC8CF-18A9-4739-9678-3C07C10AE0C6 Q38051400-1F02D2EE-AF76-46CA-865A-1F06D0D92AC4 Q38081072-1F0CFD30-D0E3-4380-9244-2B2B12EAD850 Q38325427-C7A7F403-05E1-466B-AD38-6BD9D2A33EEB Q38571596-3CC0A6AC-3D90-4E6F-A6FC-2046C4F968D1 Q38909409-8EDE8DBA-B10F-444A-A0EC-4267BB81A9CF Q38954109-8F96D18B-80BF-4762-BFE6-168374850782 Q39007008-8D9F21C0-2D62-4AAB-8B7F-25803649D0CB Q39759988-5872CB13-455C-48AD-9B69-2F161E4DC7BA Q41588370-06F172ED-FCD3-4F46-8D66-81204C909598 Q41696931-10AA4075-7A6D-491E-9614-76CB5239E637 Q41992990-CADFAC8B-4ECB-40C1-A172-B693C3521EC1 Q42215418-FF1B09D2-78EB-4C83-8195-F0B7ED7BE336 Q46158508-F75946DE-DFFA-4407-B6CD-981F60030BAA Q57076282-ACF5E8E2-0275-4854-BCBB-9E92A84A6651 Q57403878-FB8F51FB-910E-478B-AE78-F5575C3DD4E3

P2860

Atazanavir pharmacokinetics with and without tenofovir during pregnancy

http://www.wikidata.org/entity/Q35074548

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Atazanavir pharmacokinetics with and without tenofovir during pregnancy

@ast

Atazanavir pharmacokinetics with and without tenofovir during pregnancy

@en

type

label

Atazanavir pharmacokinetics with and without tenofovir during pregnancy

@ast

Atazanavir pharmacokinetics with and without tenofovir during pregnancy

@en

prefLabel

Atazanavir pharmacokinetics with and without tenofovir during pregnancy

@ast

Atazanavir pharmacokinetics with and without tenofovir during pregnancy

@en

P1433

Q35074548-620A03C2-E346-410C-B708-011BC8D54F37

P1476

Q35074548-6B56B182-FAEE-4091-B04C-515EA18EC9D0

P2093

Q35074548-21083D2E-3535-4D89-81C4-C5C995362818

Q35074548-2382C87B-1576-4E70-8F18-3C853272F16C

Q35074548-2ABFDFBF-366C-4CD4-B273-6292415AC71C

Q35074548-2C847FA1-17E5-4B23-A893-275BD088F607

Q35074548-565ED2A1-9E53-4ADE-A941-BD5EBC180A5D

Q35074548-A1D608BE-DE96-402B-8124-D7495874E1C7

Q35074548-AEF100E8-CB07-476F-9369-7901359E2CD2

Q35074548-BFB653CE-B28C-46AF-AACA-CA05DF4DBAC1

Q35074548-D6EF1D27-FA3E-4E11-B846-035416D783DE

Q35074548-FBD132B4-8548-4E7D-88DE-815C82A328E7

P2860

Q35074548-02409F79-59AA-46D7-9D2D-67A3A65A3B66

Q35074548-0F6B3A29-258A-4F58-B633-FABAF7F7B745

Q35074548-4984D666-6BEA-4D28-9D56-E93B4004635C

Q35074548-53165D70-A9D3-4471-961C-9E1BCA6B6A64

Q35074548-7192C4CF-E854-442A-ABB9-3F135438B332

Q35074548-81D220B8-53E1-4B8E-9B05-985C30965198

Q35074548-872F5146-DB46-4956-96A3-7E93F8CDC569

Q35074548-8CA94F00-219E-444C-B461-AFD0B2E83506

Q35074548-8CD565EA-5E9A-4F71-9D8A-B96884385EBD

Q35074548-A920AACB-FEF1-4C07-A2CB-103F869FA538

P304

Q35074548-30A58E7F-A78B-420F-B5B5-18AD50F8325D

P31

Q35074548-EE599A4D-6BB9-4247-B791-DD400A8C2626

P356

Q35074548-38F99C0C-340E-4FAE-B12E-CC512FA40B8B

P407

Q35074548-CE510F5F-A7C4-492A-9EDB-8D24515122F1

P433

Q35074548-E434070E-75B6-40EB-882D-41DF6CF96B50

P478

Q35074548-9C3FE2E4-4BB0-41F4-B49E-B2D85F1995DF

P50

Q35074548-A94FFC5B-61FF-43BF-9141-195E3A359B6D

P577

Q35074548-1703C4EA-DA89-4E46-A89D-D4524E072143

P698

Q35074548-EE6CBF43-315B-4186-9CF5-C0A014CC1DCD

P932

Q35074548-DD3F8FFD-8287-4552-B9C0-6A363D189594

P356

QAI.0B013E31820FD093

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Atazanavir pharmacokinetics with and without tenofovir during pregnancy

@en

P2093

Alice M Stek

http://www.w3.org/2001/XMLSchema#string

Brookie M Best

http://www.w3.org/2001/XMLSchema#string

Chengcheng Hu

http://www.w3.org/2001/XMLSchema#string

Edmund V Capparelli

http://www.w3.org/2001/XMLSchema#string

Elizabeth Hawkins

http://www.w3.org/2001/XMLSchema#string

IMPAACT 1026s Study Team

http://www.w3.org/2001/XMLSchema#string

Jennifer S Read

http://www.w3.org/2001/XMLSchema#string

Mark Mirochnick

http://www.w3.org/2001/XMLSchema#string

Michael Basar

http://www.w3.org/2001/XMLSchema#string

Sandra K Burchett

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women

Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.

Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.

Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories.

Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy

Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum.

Lopinavir exposure with an increased dose during pregnancy.

Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes.

P304

412-419

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0B013E31820FD093

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

Elizabeth Smith

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21283017

http://www.w3.org/2001/XMLSchema#string

P932

3125419

http://www.w3.org/2001/XMLSchema#string